PURPOSE: We examined how an aerobic exercise intervention influenced circulating estradiol, estrone, sex hormone-binding globulin (SHBG), androstenedione, and testosterone levels, which may be involved in the association between physical activity and breast cancer risk. METHODS: A two-center, two-arm randomized controlled trial of exercise was conducted in 320 postmenopausal, sedentary women age 50 to 74 years. Participants were randomly assigned to a 1-year aerobic exercise intervention of 225 min/wk (n = 160) or to a control group who maintained their usual level of activity (n = 160). Baseline, 6-month, and 12-month assessments of estrone, estradiol, androstenedione, and testosterone were quantified by radioimmunoassay after extraction, and SHBG was quantified by an immunometric assay. Intent-to-treat analyses were performed using linear mixed models. RESULTS:Blood data were available on 309 women (96.6%) at 12 months. Women in the intervention group exercised an average of 3.6 d/wk for 178 min/wk. At 12 months, statistically significant reductions in estradiol (treatment effect ratio [TER] = 0.93; 95% CI, 0.88 to 0.98) and free estradiol (TER = 0.91; 95% CI, 0.87 to 0.96) and increases in SHBG (TER = 1.04; 95% CI, 1.02 to 1.07) were observed in the exercise group compared with the control group. No significant differences in estrone, androstenedione, and testosterone levels were observed between exercisers and controls at 12 months. CONCLUSION: This trial found that previously sedentary postmenopausal women can adhere to a moderate- to vigorous-intensity exercise program that results in changes in estradiol and SHBG concentrations that are consistent with a lower risk for postmenopausal breast cancer.
RCT Entities:
PURPOSE: We examined how an aerobic exercise intervention influenced circulating estradiol, estrone, sex hormone-binding globulin (SHBG), androstenedione, and testosterone levels, which may be involved in the association between physical activity and breast cancer risk. METHODS: A two-center, two-arm randomized controlled trial of exercise was conducted in 320 postmenopausal, sedentary women age 50 to 74 years. Participants were randomly assigned to a 1-year aerobic exercise intervention of 225 min/wk (n = 160) or to a control group who maintained their usual level of activity (n = 160). Baseline, 6-month, and 12-month assessments of estrone, estradiol, androstenedione, and testosterone were quantified by radioimmunoassay after extraction, and SHBG was quantified by an immunometric assay. Intent-to-treat analyses were performed using linear mixed models. RESULTS: Blood data were available on 309 women (96.6%) at 12 months. Women in the intervention group exercised an average of 3.6 d/wk for 178 min/wk. At 12 months, statistically significant reductions in estradiol (treatment effect ratio [TER] = 0.93; 95% CI, 0.88 to 0.98) and free estradiol (TER = 0.91; 95% CI, 0.87 to 0.96) and increases in SHBG (TER = 1.04; 95% CI, 1.02 to 1.07) were observed in the exercise group compared with the control group. No significant differences in estrone, androstenedione, and testosterone levels were observed between exercisers and controls at 12 months. CONCLUSION: This trial found that previously sedentary postmenopausal women can adhere to a moderate- to vigorous-intensity exercise program that results in changes in estradiol and SHBG concentrations that are consistent with a lower risk for postmenopausal breast cancer.
Authors: B E Ainsworth; W L Haskell; M C Whitt; M L Irwin; A M Swartz; S J Strath; W L O'Brien; D R Bassett; K H Schmitz; P O Emplaincourt; D R Jacobs; A S Leon Journal: Med Sci Sports Exerc Date: 2000-09 Impact factor: 5.411
Authors: Anne McTiernan; Shelley S Tworoger; Cornelia M Ulrich; Yutaka Yasui; Melinda L Irwin; Kumar B Rajan; Bess Sorensen; Rebecca E Rudolph; Deborah Bowen; Frank Z Stanczyk; John D Potter; Robert S Schwartz Journal: Cancer Res Date: 2004-04-15 Impact factor: 12.701
Authors: Evelyn M Monninkhof; Miranda J Velthuis; Petra H M Peeters; Jos W R Twisk; Albertine J Schuit Journal: J Clin Oncol Date: 2009-08-17 Impact factor: 44.544
Authors: N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson Journal: Endocr Relat Cancer Date: 1999-06 Impact factor: 5.678
Authors: Sabina Rinaldi; Annabelle Geay; Henri Déchaud; Carine Biessy; Anne Zeleniuch-Jacquotte; Arslan Akhmedkhanov; Roy E Shore; Elio Riboli; Paolo Toniolo; Rudolf Kaaks Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-10 Impact factor: 4.254
Authors: Melinda L Irwin; Yutaka Yasui; Cornelia M Ulrich; Deborah Bowen; Rebecca E Rudolph; Robert S Schwartz; Michi Yukawa; Erin Aiello; John D Potter; Anne McTiernan Journal: JAMA Date: 2003-01-15 Impact factor: 56.272
Authors: Christy G Woolcott; Kerry S Courneya; Norman F Boyd; Martin J Yaffe; Tim Terry; Anne McTiernan; Rollin Brant; Rachel Ballard-Barbash; Melinda L Irwin; Charlotte A Jones; Sony Brar; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Christine M Friedenreich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: Gabriel M Pagnotti; Benjamin J Adler; Danielle E Green; M Ete Chan; Danielle M Frechette; Kenneth R Shroyer; Wesley G Beamer; Janet Rubin; Clinton T Rubin Journal: Bone Date: 2012-05-11 Impact factor: 4.398
Authors: H Irene Su; Laura Y Sue; Shirley W Flatt; Loki Natarajan; Ruth E Patterson; John P Pierce Journal: J Womens Health (Larchmt) Date: 2013-10-10 Impact factor: 2.681
Authors: E Guinan; J Hussey; J M Broderick; F E Lithander; D O'Donnell; M J Kennedy; E M Connolly Journal: Support Care Cancer Date: 2013-02-22 Impact factor: 3.603